Recognizing that the identification of individuals at risk of carrying a BRCA1 or BRCA2 pathogenic variant allows for targeted screening, prevention, and treatment, and can be lifesaving, several international guidelines recommend genetic testing for these genes within the set of possible genetic variants for individuals or patients suspected of being at risk of breast and ovarian cancer [12,13,23]. This evidence concerns the gene BRCA2 and ovarian carcinoma.